Intellia Therapeutics' shares surged after the US Food and Drug Administration lifted a clinical hold on its Phase 3 MAGNITUDE-2 trial. The decision allows patient enrollment to resume for Nexiguran Ziclumeran, a gene-editing therapy targeting ATTRv-PN, following a prior safety-related pause.